Search hospitals > California > Whittier

Presbyterian Intercommunity Hospital

Claim this profile
Whittier, California 90602
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast cancer
Conducts research for Colorectal Cancer
60 reported clinical trials
4 medical researchers
Photo of Presbyterian Intercommunity Hospital in WhittierPhoto of Presbyterian Intercommunity Hospital in WhittierPhoto of Presbyterian Intercommunity Hospital in Whittier

Summary

Presbyterian Intercommunity Hospital is a medical facility located in Whittier, California. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer, Colorectal Cancer and other specialties. Presbyterian Intercommunity Hospital is involved with conducting 60 clinical trials across 102 conditions. There are 4 research doctors associated with this hospital, such as Lisa S. Wang, Christopher R. Foss, Lisa Shing-E Lu Wang, M.D., and Edwin Y. Lin.

Area of expertise

1Lung Cancer
Global Leader
Presbyterian Intercommunity Hospital has run 25 trials for Lung Cancer. Some of their research focus areas include:
Stage II
Stage I
Stage IV
2Breast Cancer
Global Leader
Presbyterian Intercommunity Hospital has run 17 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
PR positive

Top PIs

Clinical Trials running at Presbyterian Intercommunity Hospital

Lung Cancer
Breast Cancer
Ovarian Cancer
Endometrial Cancer
Non-Small Cell Lung Cancer
Breast cancer
Cancer
ALK Gene Rearrangement
Fallopian Tube Cancer
Peritoneal Carcinoma
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Presbyterian Intercommunity Hospital?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security